We serve Chemical Name:2-Bromo-3-chlorothiophene CAS:77893-68-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Bromo-3-chlorothiophene
CAS.NO:77893-68-6
Synonyms:2-bromo-3-chloro-thiophene;2-Bromo-3-chlorothiophene;3-chloro-2-bromo-thiophene;Thiophene,2-bromo-3-chloro;Thiophene, 2-bromo-3-chloro-;2-bromanyl-3-chloranyl-thiophene
Molecular Formula:C4H2BrClS
Molecular Weight:197.481
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:202.5±20.0 °C at 760 mmHg
Density:1.8±0.1 g/cm3
Index of Refraction:1.612
PSA:28.24000
Exact Mass:195.874908
LogP:3.31
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-bromo-3-chloro-thiophene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-bromanyl-3-chloranyl-thiophene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Thiophene, 2-bromo-3-chloro- Use and application,2-bromo-3-chloro-thiophene technical grade,usp/ep/jp grade.
Related News: RELATED: With Takhzyro durability data, Takeda tries to fend off BioCryst’s hereditary angioedema challenger Orladeyo 2,6-dimethyl-1,4-benzoquinone 4-p-tosylhydrazone manufacturers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. 1-ethyl-6-iodo-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester suppliers According to Plexxikon, GSK scientists were only able to make Tafinlar after talks with Plexxikon about a potential partnership; although those talks never turned into a licensing deal, GSK apparently channeled that information and created a rival drug. hexadecane-1-sulfonic acid (3-ethyl-3H-benzothiazol-2-ylidene)-hydrazide vendor & factory.
